Vericel Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
15,622.00
19,920.00
16,340.00
19,566.00
17,286.00
8,137
Depreciation, Depletion & Amortization
489.00
752.00
1,592.00
1,886.00
1,612.00
1,426
Other Funds
4,411.00
3,722.00
2,814.00
5,949.00
4,058.00
10,331
Funds from Operations
19,544.00
22,890.00
11,934.00
11,731.00
11,616.00
3,620
Changes in Working Capital
399.00
2,520.00
1,412.00
8,161.00
1,567.00
4,032
Net Operating Cash Flow
19,943.00
25,410.00
13,346.00
19,892.00
13,183.00
412
Capital Expenditures
40.00
829.00
2,427.00
1,415.00
1,510.00
Net Investing Cash Flow
40.00
2,178.00
2,392.00
1,415.00
1,510.00
Issuance/Reduction of Debt, Net
34.00
8.00
35.00
10,249.00
6,140.00
Net Financing Cash Flow
14,404.00
49,926.00
24.00
29,704.00
18,577.00
Net Change in Cash
5,579.00
22,284.00
15,762.00
8,397.00
3,884.00
Free Cash Flow
19,983.00
26,239.00
15,773.00
21,307.00
14,693.00
Net Assets from Acquisitions
-
1,450.00
-
-
-
Other Sources
-
101.00
35.00
-
-
Change in Capital Stock
14,438.00
49,934.00
11.00
19,455.00
12,437.00
Exchange Rate Effect
-
54.00
-
-
-

About Vericel

View Profile
Address
64 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.vcel.com
Updated 07/08/2019
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee.